In patients with EGFR T790M-positive NSCLC who were receiving osimertinib after prior EGFR-TKI treatment, ctDNA was collected at pretreatment, after 1 month, and at the time of POD. This evidence concerns the gene EGFR and non-small cell lung carcinoma.